Biodesix Q2 revenue up 51% YoY to $17.9M; raises FY2024 guidance to $70-72M

BIODESIX INC

2024-Q2 EPS reported -$0.22 revenue$32,743,000

Q2 2024 revenue $17.9M, up 51% YoY; Lung Diagnostic $16.5M (+44%), Biopharma Services $1.4M (+228%).
Gross margin 78.4% vs 72.7% Q2 2023; net loss improved 19% to $10.8M; Adjusted EBITDA loss improved 38% to $5.6M.
Raises full-year 2024 revenue guidance to $70-72M from prior $65-68M.
Lung diagnostic test volume 13,900, up 42% YoY and 17% sequentially.
Cash $42.2M at June 30, 2024, including $55M from April stock offering.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.